Sugi Predict

Sugi Predict / Compounds / SCHEMBL2597215

SCHEMBL2597215

SCHEMBL2597215

CC(C)c1cc2[nH]c(=O)n(N(C(=O)CCCN3CCOCC3)S(C)(=O)=O)c(=O)c2cc1-c1ccnn1C

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ HSD17B10 Q99714 3/20 0.37
▸ HPGD P15428 2/20 0.37
▸ HTR2A P28223 6/20 0.36
▸ HTR2C P28335 5/20 0.36
▸ IMPDH2 P12268 1/20 0.36
▸ MAPK1 P28482 3/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CD274 Q9NZQ7 1/20 0.34
▸ HTR3A P46098 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ TERT O14746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2597358 0.95 IMPDH2 (0.36) ALDH1A1KDM4EHSD17B10HPGDHTR2A
SCHEMBL2597376 0.92 IMPDH2 (0.35) ALDH1A1KDM4EHSD17B10HPGDHTR2A
SCHEMBL2597335 0.89 KDM4E (0.35) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL2597264 0.88 KDM4E (0.37) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL2597262 0.88 KDM4E (0.32) ALDH1A1KDM4EHSD17B10HPGDIMPDH2
SCHEMBL2597131 0.87 KDM4E (0.36) ALDH1A1KDM4EHSD17B10HPGDMEN1
SCHEMBL2597435 0.83 LMNA (0.33) ALDH1A1KDM4EHSD17B10
SCHEMBL2597409 0.82 HAVCR2 (0.32) IMPDH2
SCHEMBL2597446 0.82 KDM4E (0.37) ALDH1A1KDM4EHSD17B10HPGDIMPDH2
SCHEMBL2597238 0.81 HAVCR2 (0.32) ALDH1A1KDM4EHSD17B10IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571865-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES Novartis AG (CH) 2013-03-27 — — EP claimed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US claimed
WO-2011144666-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG (CH) 2011-11-24 — — WO claimed
EP-2571865-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES Novartis AG (CH) 2013-03-27 — — EP disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
WO-2011144666-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG (CH) 2011-11-24 — — WO disclosed
WO-2011144666-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG (CH) 2011-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES GRIK2, GRIK1, GRIK4 ALDH1A1 387/4885KDM4E 784/4885HSD17B10 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.